Online inquiry

IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14198MR)

This product GTTS-WQ14198MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Psoriatic arthritis (PSA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14198MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14810MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ4470MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ4507MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ660MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 8H9
GTTS-WQ11692MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ10686MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ12071MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ7549MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GC33
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW